Colorectal Adenoma and Carcinoma Specific MiRNA Profiles in Biopsy and Their Expression in Plasma Specimens

Overview

Journal Clin Epigenetics

Publisher Biomed Central

Specialty Genetics

Date 2017 Mar 15

PMID 28289479

Citations 32

Authors

Zsofia Brigitta Nagy

Barnabas Wichmann

Alexandra Kalmar

Orsolya Galamb

Barbara Kinga Bartak

Sandor Spisak

Zsolt Tulassay

Bela Molnar

Affiliations

Soon will be listed here.

Abstract

Background: MiRNA expression markers are well characterized in colorectal cancer (CRC), but less is known about miRNA expression profiles in colorectal adenomas. Genome-wide miRNA and mRNA expression analyses were conducted through the colorectal adenoma dysplasia sequence. Furthermore, analysis of the expression levels of miRNAs in matched plasma samples was performed, focusing on biomarker candidates; miRNA and mRNA expression analyses were performed on colorectal biopsies and plasma samples (20 normals; 11 tubular and 9 tubulovillous adenomas; 20 colorectal carcinomas) by miRNA 3.0 and Human Transcriptome Array (Affymetrix) and validated by RT-qPCR. Microarray data were analyzed using Expression Console and mRNA targets were predicted using miRWALK 2.0.

Results: Based on microarray analysis, 447 miRNAs were expressed in tissue and 320 in plasma. Twelve were upregulated (miR-31, 8-fold < 0.001) and 11 were downregulated (miR-10b 3-fold < 0.001) in neoplastic lesions compared to normal group. Eleven miRNAs showed altered expression between adenoma subtypes (miR-183 2.8-fold change, < 0.007). Expression level of 24 miRNAs differed between adenoma and CRC groups (including miR-196a, 3.5-fold). Three miRNAs (miR-31, miR-4506, miR-452*) were differentially expressed in adenoma compared to normal both in tissue and plasma samples. miRNA expression data were confirmed by RT-PCR both in plasma and matched tissue samples.

Conclusions: MiRNAs showed characteristic expression changes during CRC development in tissue. miRNAs were also presented in plasma and positively correlated with matched tissue expression levels. The identified miRNA expression changes could be verified RT-PCR methods facilitating routine application.

Citing Articles

Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.

Zdralevic M, Radovic A, Raonic J, Popovic N, Klisic A, Vuckovic L Int J Mol Sci. 2024; 25(20).

PMID: 39456841 PMC: 11507567. DOI: 10.3390/ijms252011060.

The miRNA and PD-1/PD-L1 signaling axis: an arsenal of immunotherapeutic targets against lung cancer.

Yadav R, Khatkar R, Yap K, Kang C, Lyu J, Singh R Cell Death Discov. 2024; 10(1):414.

PMID: 39343796 PMC: 11439964. DOI: 10.1038/s41420-024-02182-1.

Sustained Effectiveness and Safety of Therapeutic miR-10a/b in Alleviating Diabetes and Gastrointestinal Dysmotility without Inducing Cancer or Inflammation in Murine Liver and Colon.

Singh R, Ha S, Park H, Debnath S, Cho H, Baek G Int J Mol Sci. 2024; 25(4).

PMID: 38396943 PMC: 10888952. DOI: 10.3390/ijms25042266.

Rebound increase in microRNA levels at the end of 5-FU-based therapy in colorectal cancer patients.

Badr D, Fouad M, Hussein M, Salem S, Zekri A, Shouman S Sci Rep. 2023; 13(1):14237.

PMID: 37648713 PMC: 10469181. DOI: 10.1038/s41598-023-41030-7.

MicroRNA expression associated with low-grade cervical intraepithelial neoplasia outcomes.

Winters A, Berry A, Dewenter T, Chowdhury N, Wright K, Cameron J J Cancer Res Clin Oncol. 2023; 149(13):11969-11978.

PMID: 37421453 PMC: 10465678. DOI: 10.1007/s00432-023-05023-3.

References

Ruan J, Chen H, Kurgan L, Chen K, Kang C, Pu P . HuMiTar: a sequence-based method for prediction of human microRNA targets. Algorithms Mol Biol. 2008; 3:16. PMC: 2631598. DOI: 10.1186/1748-7188-3-16. View

Zhang N, Shen Q, Zhang P . miR-497 suppresses epithelial-mesenchymal transition and metastasis in colorectal cancer cells by targeting fos-related antigen-1. Onco Targets Ther. 2016; 9:6597-6604. PMC: 5087769. DOI: 10.2147/OTT.S114609. View

Balaguer F, Moreira L, Lozano J, Link A, Ramirez G, Shen Y . Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res. 2011; 17(19):6239-49. PMC: 3186834. DOI: 10.1158/1078-0432.CCR-11-1424. View

Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M . Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006; 9(3):189-98. DOI: 10.1016/j.ccr.2006.01.025. View

Gattolliat C, Uguen A, Pesson M, Trillet K, Simon B, Doucet L . MicroRNA and targeted mRNA expression profiling analysis in human colorectal adenomas and adenocarcinomas. Eur J Cancer. 2015; 51(3):409-20. DOI: 10.1016/j.ejca.2014.12.007. View

Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N . Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2009; 18(6):1888-93. DOI: 10.1158/1055-9965.EPI-08-0937. View

Chang K, Miller N, Kheirelseid E, Lemetre C, Ball G, Smith M . MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis. 2011; 26(11):1415-22. DOI: 10.1007/s00384-011-1279-4. View

Fearon E, Vogelstein B . A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5):759-67. DOI: 10.1016/0092-8674(90)90186-i. View

Wu C, Ng S, Dong Y, Ng S, Leung W, Lee C . Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2011; 61(5):739-45. DOI: 10.1136/gut.2011.239236. View

10.

Galamb O, Spisak S, Sipos F, Toth K, Solymosi N, Wichmann B . Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer. 2010; 102(4):765-73. PMC: 2837560. DOI: 10.1038/sj.bjc.6605515. View

11.

Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y . Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res. 2011; 17(7):1722-30. DOI: 10.1158/1078-0432.CCR-10-1800. View

12.

Hibino Y, Sakamoto N, Naito Y, Goto K, Oo H, Sentani K . Significance of miR-148a in Colorectal Neoplasia: Downregulation of miR-148a Contributes to the Carcinogenesis and Cell Invasion of Colorectal Cancer. Pathobiology. 2015; 82(5):233-41. DOI: 10.1159/000438826. View

13.

Kinzler K, Vogelstein B . Lessons from hereditary colorectal cancer. Cell. 1996; 87(2):159-70. DOI: 10.1016/s0092-8674(00)81333-1. View

14.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

15.

Schopman N, Heynen S, Haasnoot J, Berkhout B . A miRNA-tRNA mix-up: tRNA origin of proposed miRNA. RNA Biol. 2010; 7(5):573-6. DOI: 10.4161/rna.7.5.13141. View

16.

Tarasov V, Matishov D, Shin E, Boiko N, Timoshkina N, Makhotkin M . [Coordinated aberranit expression of miRNAs in colon cancer]. Genetika. 2015; 50(10):1232-44. View

17.

Liu H, Song Z, Liao D, Zhang T, Liu F, Zheng W . miR-503 inhibits cell proliferation and invasion in glioma by targeting L1CAM. Int J Clin Exp Med. 2016; 8(10):18441-7. PMC: 4694350. View

18.

Patai A, Valcz G, Hollosi P, Kalmar A, Peterfia B, Patai A . Comprehensive DNA Methylation Analysis Reveals a Common Ten-Gene Methylation Signature in Colorectal Adenomas and Carcinomas. PLoS One. 2015; 10(8):e0133836. PMC: 4546193. DOI: 10.1371/journal.pone.0133836. View

19.

Papadopoulos G, Reczko M, Simossis V, Sethupathy P, Hatzigeorgiou A . The database of experimentally supported targets: a functional update of TarBase. Nucleic Acids Res. 2008; 37(Database issue):D155-8. PMC: 2686456. DOI: 10.1093/nar/gkn809. View

20.

Zhang H, Gu G, Zhang X, Li F, Ding L, Fan Q . Primary analysis and screening of microRNAs in gastric cancer side population cells. World J Gastroenterol. 2015; 21(12):3519-26. PMC: 4375573. DOI: 10.3748/wjg.v21.i12.3519. View